Recent Advances in Glucocorticoid Receptor Action by A. CatoRecent Advances in Glucocorticoid Receptor Action by A. Cato

Recent Advances in Glucocorticoid Receptor Action

byA. CatoEditorH. Schaecke, K. Asadullah

Paperback | October 3, 2013

Pricing and Purchase Info

$250.84 online 
$303.95 list price save 17%
Earn 1,254 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


Since 1948, hydrocortisone (cortisol), the principal glucocorticoid (GC) of the human adrenal cortex has been successfully used at phar­ macological concentrations for the suppression of clinical manifesta­ tions of rheumatoid arthritis. Numerous compounds with GC activity have also been developed and used. Fifty years after their initial clinical use, GCs are still the most im­ portant and frequently prescribed class of anti-inflammatory drugs for various inflammatory disorders. They are administered either orally, parenterally (intravenous, intramuscular, intrathecal), or topically (cu­ taneous, intranasal, pulmonic, rectal). Despite the many beneficial ef­ fects of GCs, they also have their limitations and disadvantages that occur with varying prevalence on different organs and after different durations of therapy. These side-effects can range in severity from cos­ metic (e.g. telangiectasias, hypertrichosis) to seriously disabling (e.g. induction of glaucoma, diabetes, osteoporosis) or even life-threatening disorders (e.g. gastric haemorrhage). These adverse effects of GCs se­ riously handicap their successful use as anti-inflammatory agents. There is therefore a strong need for the development of substances with the anti-inflammatory potency of classical GCs but with reduced side-effects.
Title:Recent Advances in Glucocorticoid Receptor ActionFormat:PaperbackDimensions:380 pagesPublished:October 3, 2013Publisher:Springer NatureLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:3662046628

ISBN - 13:9783662046623

Look for similar items by category:


Table of Contents

P.J. Barnes: Glucocorticoids and Asthma; H.-D. Volk: Immunomonitoring of GC Therapy; W.Sterry and K. Asadullah: Topical GC Therapy in Dermatology;H.K. Väänänen and P.L. Härkönen: Bone Effects of GC Therapy; U.Pleyer and Z. Sherif: Corticosteroids in Ophtalmology; U.Wahn: Special Problems in GC Treatment of Children; D.D. DeFranco: Functional Implications of GC Receptor Trafficking;G.L.Hager: The Dynamics of Intranuclear Movement of Chromatin Remodeling by the GC Receptor; C. Caelles et al.: GC Receptor Anatgonism of AP-1 Activity by Inhibition of MAPK Family; O. Kassel and A.C.B. Cato: Mast Cells as Targets for GC in the Treatment of Allergic Disorders;A.-C. Wikström et al.: Cytosolic GC Receptor Interacting Proteins; M.J.M. Schaaf and J.A. Cidlowski: The GC Receptor ß-isoform: A Perspective on its Relevance in Human Health and Disease; B. Groner and C. Shemanko:. Cooperation of Nuclear Transcription Factors Regulated by Steroid and Peptide Hormones; W. Vanden Berghe et al.: Induction and Repression of NF-kB-driven Inflammatory Genes; A. Dostert and T. Heinzel: DNA-dependent Cofactor Selectivity of the GC Receptor; P. Herrlich: Cofactor Requirement for Transcriptional Crosstalk between the GC Receptor and Other Transcription Factors; C.Kellendonk et al.; X Analysis of GC Receptor Function by Gene Targeting Analysis in the Mouse; P. Mittelstadt et al.: Glucocorticoid-inducible Genes that Regulate T-Cell Function; U. Egner: Structural Analysis of the GR Ligand-binding Domain; H. Schäcke et al.: Selective GC Receptor Agonists (SEGRAs): A Novel Class of Antiinflammatory Compounds;